Bafadhel, MonaFaner, RosaTaillé, CamilleRussell, Richard E. K.Welte, TobiasBarnes, Peter J.Agustí García-Navarro, Àlvar2023-05-112023-05-1120220905-9180https://hdl.handle.net/2445/197869The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms13 p.application/pdfengcc-by (c) Bafadhel, Mona et al., 2022https://creativecommons.org/licenses/by/4.0/AsmaCorticosteroidesCOVID-19SARS-CoV-2AsthmaAdrenocortical hormonesCOVID-19SARS-CoV-2info:eu-repo/semantics/article7277362023-05-11info:eu-repo/semantics/openAccess9332994